Chen-Chi Wu1,2, Ching-Hui Tsai3, Chia-Cheng Hung4,5, Yin-Hung Lin1,4, Yi-Hsin Lin1, Fang-Li Huang1, Po-Nien Tsao6, Yi-Ning Su5,7,8, Yungling Leo Lee3,9, Wu-Shiun Hsieh6, Chuan-Jen Hsu1,10. 1. Department of Otolaryngology, National Taiwan University Hospital, Taipei, Taiwan. 2. Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan. 3. Institute of Epidemiology and Preventive Medicine, National Taiwan University College of Public Health, Taipei, Taiwan. 4. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan. 5. Sofiva Genomics Co., Ltd., Taipei, Taiwan. 6. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. 7. Dianthus Maternal Fetal Medicine Clinic, Taipei, Taiwan. 8. Department of Obstetrics and Gynecology, School of Medicine, Taipei Medical University, Taipei, Taiwan. 9. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. 10. Department of Otolaryngology, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung, Taiwan.
Abstract
PURPOSE: The feasibility of genetic screening for deafness-causing mutations in newborns has been reported in several studies. The aim of this study was to investigate the long-term results in those who screened positive for deafness mutations; these results are crucial to determine the cost-effectiveness to justify population-wide genetic screening. METHODS: We performed simultaneous hearing screening and genetic screening targeting four common deafness mutations (p.V37I and c.235delC of GJB2, c.919-2A>G of SLC26A4, and the mitochondrial m.1555A>G) in 5173 newborns at a tertiary hospital between 2009 and 2015. Serial audiometric results up to 6 years old were then analyzed in children with conclusive genotypes. RESULTS: Newborn genetic screening identified 82 (1.6%) babies with conclusive genotypes, comprising 62 (1.2%) with GJB2 p.V37I/p.V37I, 16 (0.3%) with GJB2 p.V37I/c.235delC, and 4 (0.1%) with m.1555A>G. Of these, 46 (56.1%) passed hearing screening at birth. Long-term follow-up demonstrated progressive hearing loss in children with the GJB2 p.V37I/p.V37I and p.V37I/c.235delC genotypes; this hearing loss deteriorated by approximately 1 decibel hearing level (dBHL) per year. CONCLUSIONS: We delineated the longitudinal auditory features of the highly prevalent GJB2 p.V37I mutation on a general population basis and confirmed the utility of newborn genetic screening in identifying infants with late-onset or progressive hearing impairment undetectable by newborn hearing screening.Genet Med 19 1, 6-12.
PURPOSE: The feasibility of genetic screening for deafness-causing mutations in newborns has been reported in several studies. The aim of this study was to investigate the long-term results in those who screened positive for deafness mutations; these results are crucial to determine the cost-effectiveness to justify population-wide genetic screening. METHODS: We performed simultaneous hearing screening and genetic screening targeting four common deafness mutations (p.V37I and c.235delC of GJB2, c.919-2A>G of SLC26A4, and the mitochondrial m.1555A>G) in 5173 newborns at a tertiary hospital between 2009 and 2015. Serial audiometric results up to 6 years old were then analyzed in children with conclusive genotypes. RESULTS: Newborn genetic screening identified 82 (1.6%) babies with conclusive genotypes, comprising 62 (1.2%) with GJB2 p.V37I/p.V37I, 16 (0.3%) with GJB2 p.V37I/c.235delC, and 4 (0.1%) with m.1555A>G. Of these, 46 (56.1%) passed hearing screening at birth. Long-term follow-up demonstrated progressive hearing loss in children with the GJB2 p.V37I/p.V37I and p.V37I/c.235delC genotypes; this hearing loss deteriorated by approximately 1 decibel hearing level (dBHL) per year. CONCLUSIONS: We delineated the longitudinal auditory features of the highly prevalent GJB2 p.V37I mutation on a general population basis and confirmed the utility of newborn genetic screening in identifying infants with late-onset or progressive hearing impairment undetectable by newborn hearing screening.Genet Med 19 1, 6-12.
Authors: D Wattanasirichaigoon; C Limwongse; C Jariengprasert; P T Yenchitsomanus; C Tocharoenthanaphol; W Thongnoppakhun; C Thawil; D Charoenpipop; T Pho-iam; S Thongpradit; P Duggal Journal: Clin Genet Date: 2004-11 Impact factor: 4.438
Authors: Colin R Kennedy; Donna C McCann; Michael J Campbell; Catherine M Law; Mark Mullee; Stavros Petrou; Peter Watkin; Sarah Worsfold; Ho Ming Yuen; Jim Stevenson Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245
Authors: Christine D'Aguillo; Sara Bressler; Denise Yan; Rahul Mittal; Robert Fifer; Susan H Blanton; Xuezhong Liu Journal: Int J Audiol Date: 2019-07-02 Impact factor: 2.117
Authors: Karl W Doerfer; Tara Sander; Girija G Konduri; David R Friedland; Joseph E Kerschner; Christina L Runge Journal: Laryngoscope Investig Otolaryngol Date: 2020-05-20